Thomas de Vlaam is the founder and CEO of Amylon Therapeutics, He holds a bachelor's degree in International Medicine and Global Health from the University of Groningen which he studied with the ambition of becoming a neurosurgeon. Unfortunately after a diagnosis of Scheuermann’s disease, Thomas underwent significant spinal fusion surgery in 2011, forcing him to give up on his medical career. Despite the physical challenges and long recovery periods, his dream of helping patients a grew stronger and became an unstoppable driver. He joined ProQR – a biotech company in the Netherlands working on novel drugs to treat rare orphan disorders. As their head of CNS he invented and developed a complete new approach to treat Amyloid disorders and decided to start a new company: Amylon. With some initial capital, that idea turned into Amylon's lead program, a breakthrough therapy for one of today’s most important unmet medical needs.
Daniel Curtis Ph.D is our Chief Development Officer. Dan joined us in June 2018 having previously held leadership roles with Novartis Institutes for Biomedical Research (NIBR). Dr.Curtis received his B.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, his Ph. D, Biological Chemistry and Molecular Pharmacology from Harvard University, and worked as a Postdoctoral Fellow at the Whitehead Institute for Biomedical Research. He has authored more than 30 articles in the field of neurology, biological chemistry and molecular pharmacology.
Dinko Valerio is a scientist and an experienced biotech entrepreneur with experience in both public and private companies as CEO and board member. Mr. Valerio is founder and former CEO of Crucell N.V., a Dutch biotech company, and founder and former general partner of Aescap Venture, a life sciences venture capital firm. Mr. Valerio is a professor in the field of gene therapy of the hematopoietic system at the University of Leiden. He is an author on more than 100 articles in peer-reviewed journals and an inventor on 11 patent-families
Dr. Bo Jesper Hansen has been a key figure in shaping the modern European orphan disease market. He previously served as the president and CEO of Swedish Orphan International AB where he was directly involved in bringing over 60 products to market. He is an Author of more than 40 publications in international peer-review scientific journals and has an M.D. in Urology and a Ph.D. from the University of Copenhagen.
Thomas Wisniewski is the director of Alzheimer’s disease Center at NYU School of medicine. Dr. Wisniewski obtained his medical degree at Kings College School of Medicine in the UK. He did his Neurology and Neuropathology Residencies at NYU and Columbia-Presbyterian, respectively. He is a board-certified Neurologist and Neuropathologist, who runs an active research laboratory focusing on neurodegenerative disorders, in particular the mechanisms which drive Amyloid deposition in Alzheimer's and prion related diseases.
Philip Scheltens is director and founder of the Alzheimer Center VUmc Amsterdam. In 2011 he was also appointed scientific director at ‘Pearlstring Institute’ (Parelsnoer Instituut) and appointed member of ‘Royal Academy of Arts and Sciences’ (Koninklijke Academie van Kunsten en Wetenschappen). Under his supervision more than 50 theses appeared and there are more than 665 publications to his name. He is active in many fields and is the initiator of the ‘Deltaplan Dementia’ (Deltaplan Dementie).